Skip to Content
Corporate Sponsorships
Member Login
Search
Member Login
Give
Corporate Sponsorship
SEARCH
About Us
About ASTCT
Board of Directors
President Message
Partner Organizations
For Media
Contact ASTCT
Committees
Membership
Volunteer With ASTCT
Become a Member
Member Spotlights
Member Directory
Special Interest Groups
Community Forum
Mentor Match
Education
Practice Guidelines
Learning Center
Patient Education
Coverage, Coding, Billing
CAR-T Therapy Coding and Billing Guide
HCT Coding and Billing Resources
Payer RFI Forms
Meetings
Meetings
Meetings Calendar
Clinical Research Training Course
Fundamentals of Transplant and Cellular Therapy
Gene Therapy Summit
Publications & Podcasts
Journal: Transplantation and Cellular Therapy
Trending Topics: Nucleus
Podcast: ASTCT Talks
Newsletters
Tandem Meetings News
Careers
Career Center
Fellowship Programs
Fellowship Connections
Grants
Awards
Advocacy
ASTCT Advocacy
Policy Updates
Policy Letters and Statements
ACCESS Initiative
Hill Day
Trending topics and news in HCT and Cellular Therapy
Topics to Explore
ASTCT NEWS
CAR T
GVHD
TIL
SCIENCE HIGHLIGHTS
MORE TOPICS
BISPECIFICS
MRD
NM Submissions
CAR T
Beyond Age and Performance Status: Frailty and Fitness Assessment for Hematopoietic Cell Transplantation and CAR T-Cell Therapy
by Marco Ruiz, Marc J. Braunstein
As transplantation and cellular therapy expand to older patient populations, defining fitness has become increasingly complex. In this thought leadership article, Marco Ruiz, MD, MPH, MSc,...
RECENT INSIGHTS
CAR T
Beyond Age and Performance Status: Frailty and Fitness Assessment for Hematopoietic Cell Transplantation and CAR T-Cell Therapy
by Marco Ruiz, Marc J. Braunstein
As transplantation and cellular therapy expand to older patient populations, defining fitness has become increasingly complex. In this thought leadership article, Marco Ruiz, MD, MPH, MSc,...
Science Highlights
IL13Rα2 CAR T Cells for Recurrent Glioma
by Clinical Cancer Research
The efficacy of chimeric antigen receptor (CAR) T-cell therapy targeting interleukin 13 receptor α2 (IL13Rα2) for patients with malignant gliomas has yet to be determined, but Phase I evidence...